Association of human leucocyte antigen phenotype with vaccine efficacy in patients receiving vaginal mucosal immunization for recurrent urinary tract infection.
Immune responses to specific antigens can be influenced by an individual's genetic make-up. We examined whether the efficacy of a vaginal mucosal vaccine for urinary tract infections (UTI) was affected by a patient's human leucocyte antigen (HLA) phenotype. Urinary tract infection data and the HLA phenotypes of 47 women participating in a phase II clinical trial of immunization for recurrent UTI were statistically analysed for associations between HLA-A, -B, -DR, or -DQ phenotype and postimmunization infection course. Women who received the vaccine and had HLA-DR phenotypes other than DR2 had significantly delayed times to re-infection compared with women receiving placebo. Vaccine-treated patients with the HLA-DR2 phenotype had re-infection courses that were not different than women receiving placebo. These results indicate that the efficacy of a vaginal mucosal UTI vaccine may be influenced by an individual's HLA-DR phenotype.
Hopkins
W J
WJ
Department of Surgery, University of Wisconsin Medical School, Madison 53792, USA.
Heisey
D M
DM
Uehling
D T
DT
D001424:Bacterial Infections / Q000235:genetics / Q000276:immunology / Q000517:prevention & control*; D001428:Bacterial Vaccines / Q000494:pharmacology*; D005260:Female; D006680:HLA Antigens / Q000235:genetics*; D015802:HLA-DR2 Antigen / Q000235:genetics; D006801:Humans; D018928:Immunity, Mucosal / Q000235:genetics; D007125:Immunogenetics; D010641:Phenotype; D014552:Urinary Tract Infections / Q000235:genetics / Q000276:immunology / Q000517:prevention & control*; D014621:Vagina / Q000276:immunology